Curis, Inc. (NASDAQ:CRIS) tinted gains of +3.37% (+0.06 points) to US$1.84. The volume of 0.15 Million shares climbed down over an trading activity of 425.12 Million shares. EPS ratio determined by looking at last 12 month figures is -1.59. Over the same time span, the stock marked US$11.35 as its best level and the lowest price reached was US$1.57. The corporation has a market cap of US$56.05 Million.

Curis, Inc. (NASDAQ:CRIS)’s earnings per share has been growing at a -11.5 percent rate over the past 5 year when average revenue increase was noted as -10.2 percent. The return on equity ratio or ROE stands at -247.4 percent while most common profitability ratio return on investment (ROI) was -75.9 percent. The company’s institutional ownership is monitored at 41.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 95 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.5. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) is worth US$22.22 Million and has recently risen 3.31% to US$0.46. The latest exchange of 0.07 Million shares is below its average trading activity of 194.64 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$3.04 while the mean 12-month price target for the shares is US$1.25.

Currently, the stock carries a price to earnings ratio of 0.4, a price to book ratio of 0.65, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 67.4%. With an institutional ownership near 10.3%, it carries an earnings per share ratio of 1.17.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.